Novacyt S.A. (NVYTF) has released an update.
Novacyt S.A., a prominent molecular diagnostics company, has announced the dismissal of the Department of Health and Social Care’s (DHSC) application for summary judgment by Mrs Justice Jefford. The pre-trial review has concluded, setting the stage for a trial scheduled between June 10 and July 4, 2024, with the final judgment to be reserved beyond this period. Novacyt operates across multiple sectors and is known for its extensive portfolio in human clinical diagnostics, next-generation instrumentation, and research services.
For further insights into NVYTF stock, check out TipRanks’ Stock Analysis page.
